Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma-Reference-Cited by-同舟云学术

Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma

Published:2020-09-02 Issue:17 Volume:4 Page:4086-4090
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Hashmi Hamza¹^ORCID,Mirza Abu-Sayeef²,Darwin Alicia³^ORCID,Logothetis Constantine²,Garcia Franco²,Kommalapati Anuhya⁴,Mhaskar Rahul S.⁵,Bachmeier Christina¹^ORCID,Chavez Julio C.⁴⁶,Shah Bijal⁴⁶,Pinilla-Ibarz Javier⁴⁶,Khimani Farhad¹⁶,Lazaryan Aleksandr¹⁶^ORCID,Liu Hien¹⁶^ORCID,Davila Marco L.¹⁶^ORCID,Locke Frederick L.¹⁶,Nishihori Taiga¹⁶^ORCID,Jain Michael D.¹⁶^ORCID

Affiliation:

1. Department of Blood & Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL;

2. Department of Internal Medicine and

3. Morsani College of Medicine, University of South Florida, Tampa, FL;

4. Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL; and

5. Office of Research, Innovation & Scholarly Endeavors (RISE) and

6. Department of Oncologic Sciences, Morsani College of Medicine, University of South Florida, Tampa, FL

Abstract

Key Points VTE developed in 11% of lymphoma patients after CAR T-cell therapy and was managed safely with anticoagulation. Coagulation abnormalities after CAR T-cell therapy occur but do not commonly lead to bleeding events.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/4/17/4086/1756970/advancesadv2020002060.pdf

Reference16 articles.

1. Venous thromboembolism and cancer;Baron;Lancet,1998

2. Unexpected neurologic complications following a novel lymphoma treatment “expected” to give rise to neurologic toxicity;Kersten;BMJ Case Rep,2019

3. Coexistence of a huge venous thromboembolism and bleeding tendency in cytokine release syndrome during CAR-T therapy;Liu;Blood,2019

4. Chimeric antigen receptor T-cell therapy—assessment and management of toxicities;Neelapu;Nat Rev Clin Oncol,2018

5. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma;Locke;Mol Ther,2017

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of bone disease with concurrent chimeric antigen receptor T-cell therapy for multiple myeloma;Critical Reviews in Oncology/Hematology;2024-09

2. CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations;Blood Advances;2024-08-16

3. Venous Thromboembolism Risk in Hematological Malignancies Post-Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: A Meta-Analysis of Phase 2 and Phase 3 Clinical Trials;Current Oncology;2024-07-30

4. A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy;Nature Medicine;2024-07-08

5. A meta-analysis to assess the risk of bleeding and thrombosis following chimeric antigen receptor T-cell therapy: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy;Journal of Thrombosis and Haemostasis;2024-07